Common Stock, Shares, Outstanding of Apellis Pharmaceuticals, Inc. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Apellis Pharmaceuticals, Inc. quarterly Common Stock, Shares, Outstanding in shares history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • Apellis Pharmaceuticals, Inc. Common Stock, Shares, Outstanding for the quarter ending 31 Dec 2025 was 126,621,000, a 1.7% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Common Stock, Shares, Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 126,621,000 +2,126,000 +1.7% 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 126,500,000 +4,431,000 +3.6% 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 126,187,000 +4,500,000 +3.7% 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 125,661,000 +4,394,000 +3.6% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 124,495,000 +4,939,000 +4.1% 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 122,069,000 +3,710,000 +3.1% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 121,687,000 +4,108,000 +3.5% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 121,267,000 +5,088,000 +4.4% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 119,556,000 +8,784,000 +7.9% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 118,359,000 +7,883,000 +7.1% 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 117,579,000 +10,738,000 +10% 30 Jun 2023 10-Q 31 Jul 2023 2023 Q2
Q1 2023 116,179,000 +9,739,000 +9.2% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 110,772,000 +13,248,000 +14% 31 Dec 2022 10-K/A 29 Feb 2024 2023 FY
Q3 2022 110,476,000 +23,257,000 +27% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 106,841,000 +25,885,000 +32% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 106,440,000 +26,002,000 +32% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 97,524,000 +21,394,000 +28% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 87,219,000 +11,519,000 +15% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 80,956,000 +5,356,000 +7.1% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 80,438,000 +5,038,000 +6.7% 31 Mar 2021 10-Q 28 Apr 2021 2021 Q1
Q4 2020 76,130,000 +12,192,000 +19% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 75,700,000 +11,827,238 +19% 30 Sep 2020 10-Q 02 Nov 2020 2020 Q3
Q2 2020 75,600,000 +11,927,570 +19% 30 Jun 2020 10-Q 30 Jul 2020 2020 Q2
Q1 2020 75,400,000 +12,181,524 +19% 31 Mar 2020 10-Q 29 Apr 2020 2020 Q1
Q4 2019 63,938,000 +7,658,693 +14% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 63,872,762 +7,630,191 +14% 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 63,672,430 +7,517,992 +13% 30 Jun 2019 10-Q 31 Jul 2019 2019 Q2
Q1 2019 63,218,476 +12,789,456 +25% 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 56,279,307 +5,945,155 +12% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 56,242,571 +47,769,668 +564% 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q2 2018 56,154,438 30 Jun 2018 10-Q 31 Jul 2018 2018 Q2
Q1 2018 50,429,020 31 Mar 2018 10-Q 30 Apr 2018 2018 Q1
Q4 2017 50,334,152 +41,905,786 +497% 31 Dec 2017 10-K 26 Feb 2019 2018 FY
Q3 2017 8,472,903 30 Sep 2017 10-Q 20 Dec 2017 2017 Q3
Q4 2016 8,428,366 31 Dec 2016 10-K 19 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.